Skip to content
Toggle main navigation
adMare Community logo
adMare Community logo
      Log in
      Join now
      Select an available language
      EN

      News

      Stay up-to-date on the latest industry news, with access to the most recent and relevant stories from biotechnology, pharmaceutical and life science organizations across Canada.

      Filter by category
      All
      adMare ecosystem
      Industry news
      Life science organizations

      Results (44)

      Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic

      Cancer Research UK and KisoJi Biotechnology Collaborate to Advance the First Naked Antibody Against TROP2 Into the Clinic

      LONDON and MONTREAL, Oct. 24, 2024 -- Cancer Research UK, one of the world's largest funders of cancer research, and KisoJi Biotechnology Inc., a company focussed on the discovery and development of antibody therapeutics, have signed a landmark agreement to bring KisoJi's lead asset, KJ-103, into a first-in-human clinical trial. KJ-103 is a naked anti-TROP2 antibody that has been created by KisoJi
      October 24, 2024
      Epitopea Closes USD $31 million Pre-Series A Financing

      Epitopea Closes USD $31 million Pre-Series A Financing

      CAMBRIDGE, UK and MONTREAL, CANADA, 24 October 2024 - Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, announces the closing of a USD $31 million pre-Series A financing.The pre-Series A financing brings the total capital raised by Epitopea to over USD $45 million. New investors Investissement Québec, adMare BioInnovations an
      October 24, 2024
      Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

      Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

      MONTREAL, October 21 2024 – Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced initiation of dosing in its Phase 1 clinical study of FTX-101 in healthy volunteers. FTX-101 is a first-in-class therapeutic peptide that modulates the Plexin A1 / Neuropilin 1 transmembrane receptor complex in th
      October 21, 2024
      Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

      Thryv Therapeutics Receives Positive Top-Line Results from Wave I Part 2 Clinical Study in Long QT Syndrome Type 2 and Type 3 Patients

      Montreal, Quebec – October 15, 2024 – Thryv Therapeutics Inc., a clinical-stage biotechnology company, received positive top-line results from the Wave I Part 2 proof-of-concept clinical study evaluating LQT-1213 for the treatment of congenital Long QT Syndrome (cLQTS) Types 2 and 3. LQT-1213, a potent and selective serum glucocorticoid inducible kinase 1 (SGK1) inhibitor, demonstrated clinically
      October 15, 2024
      adMare BioInnovations Appoints Marc Rivière to its Board of Directors

      adMare BioInnovations Appoints Marc Rivière to its Board of Directors

      Vancouver (BC), Toronto (ON), and Montreal (QC) – September 20, 2024 – adMare BioInnovations (adMare) is pleased to announce the appointment of Dr. Marc Rivière to its Board of Directors. With extensive expertise in funding and supporting companies, combined with a strong background in drug development, his experience will be valuable in supporting adMare’s mission of building companies, building
      September 20, 2024
      Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec

      Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec

      MONTREAL, September 16, 2024 – Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced the closing of a $8.1 million (CAD$11 million) convertible note financing led by Investissement Québec with participation from current investors CTI Life Sciences Fund and adMare BioInnovations. The proceeds of the convertibl
      September 16, 2024
      Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

      Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

      SOUTH SAN FRANCISCO, CA, September 5, 2024 – Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABD-147 for the treatment of neuroendocrine carcinoma. ABD-147
      September 5, 2024
      PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

      PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

      September 4, 2024, Burlington, MA – PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that it has entered into an exclusive licensing agreement with FORUS Therapeutics Inc (“FORUS”) for the registration and distribution of BESRE
      September 4, 2024
      FDA clears Find’s IND for Phase 1 study of FTX-101

      FDA clears Find’s IND for Phase 1 study of FTX-101

      Phase 1 study to assess safety of FTX-101, a therapeutic agent under development for regeneration of damaged myelin in Chronic Optic NeuropathyCompany expects study to commence in Q4 2024We are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for FTX-101, enabling the company to initiate its planned Phase 1 clinical
      August 27, 2024
      adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs

      adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs

      Vancouver (BC), Toronto (ON), and Montreal (QC) – August 14, 2024 – adMare BioInnovations (adMare) is delighted to open applications for the Fall 2024 cohorts of the adMare Academy BioInnovation Scientist Programs (BIS): Foundations and Industry Essentials. "Equipping emerging professionals with essential skills and knowledge ensures a robust pipeline of Canadian talent to drive the future of our
      August 14, 2024
      Sutter Health Deploys World’s First Wearable Doppler Ultrasound Patch to Enhance Safety of ICU Patients

      Sutter Health Deploys World’s First Wearable Doppler Ultrasound Patch to Enhance Safety of ICU Patients

      SACRAMENTO, Calif. and SUDBURY, Canada, July 23, 2024 — Flosonics Medical, a leader in wearable medical ultrasound, today announced that Sutter Health, an integrated not-for-profit system based in Northern California, will implement FloPatch, the world’s first wireless, wearable Doppler ultrasound. The FDA-cleared device gives ICU clinicians a fast, hands-free method of assessing blood-flow at the
      July 31, 2024
      Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

      Defence Receives No Objection Letter from Health Canada for Phase I Trial of Its ACCUM-002 (AccuTOX) as an Anti-Cancer Molecule in Patients with Melanoma

      Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that it received a No Objection Letter ("NOL") from Health Canada for its Clinical Trial Study number ACCUM-00
      July 9, 2024
      adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver

      adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver

      Vancouver (BC) - June 28, 2024 – adMare BioInnovations is delighted to announce the location of its new wet laboratory facility to support emerging life sciences companies in Vancouver, made possible through the support of the Ministry of Jobs, Economic Development and Innovation (JEDI).“As part of B.C.’s Life Sciences and Biomanufacturing Strategy, the Province is investing $10 million in this ne
      June 28, 2024
      Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

      Abdera Therapeutics Announces FDA Fast Track Designation for ABD-147, a Next-Generation Precision Radiopharmaceutical Therapy, for the Treatment of Patients with Extensive-stage Small Cell Lung Cancer

      SOUTH SAN FRANCISCO, CA, June 27, 2024 – Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABD-147 for the treatment of patients with extensive stage small ce
      June 27, 2024
      adMare Academy Opens Applications for Cohort VII of its Executive Institute

      adMare Academy Opens Applications for Cohort VII of its Executive Institute

      Vancouver (BC), Toronto (ON), and Montreal (QC) (June 11, 2024) – The adMare Academy is pleased to open applications for Cohort VII of its Executive Institute and invites senior executives working in life sciences companies across Canada to apply. The Executive Institute is at the forefront of addressing Canada's talent shortage by empowering established and emerging biotech leaders with the criti
      June 11, 2024
      Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

      Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

      CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Jun. 10, 2024-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.“Camonsertib has demonstrated a promising signal of p
      June 10, 2024
      Zymeworks Announces China NMPA Acceptance Of Biologics License Application For Zanidatamab For Second-Line Treatment Of Biliary Tract Cancer

      Zymeworks Announces China NMPA Acceptance Of Biologics License Application For Zanidatamab For Second-Line Treatment Of Biliary Tract Cancer

      VANCOUVER, British Columbia, June 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has acce
      June 10, 2024
      Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

      Domain Therapeutics strengthens its intellectual property for its series of Treg depleting anti-CCR8 antibodies, including best-in-class candidate DT-7012

      Strasbourg, France – Montreal, Canada – Boston, United States June 5, 2024 – Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptor (GPCR) driven immuno-resistance, today announces the publication of three international PCT patent applications.Expanding geograph
      June 6, 2024
      Growing our Life Sciences Sector: An Interview with Gordon McCauley

      Growing our Life Sciences Sector: An Interview with Gordon McCauley

      In January, Toronto's life sciences community gathered at the Board to identify and discuss the pressing challenges facing the sector. Attracting capital investment and establishing anchor companies emerged as critical hurdles preventing our region from achieving global leadership akin to hubs like Boston.Building on the insights gained from the symposium, the Board launched a "Life Sciences Break
      May 24, 2024
      Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

      Abdera Therapeutics Announces FDA Clearance of IND Application for ABD-147

      SOUTH SAN FRANCISCO, CA – Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr platform to design and develop tunable, precision radiopharmaceuticals for cancer, announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for ABD-147, the first delta-like ligand 3 (DLL3) targetin
      May 23, 2024
      Contact
      adMare BioInnovations

      Canada

      thansen@admarebio.com
      Cookies
      Reselect cookie settings
      Community engagement platform by Hivebrite.